Comparing Nateglinide and Gliclazide with Metformin for Type 2 Diabetes
Author Information
Author(s): Ristic S, Collober-Maugeais C, Pecher E, Cressier F
Primary Institution: Novartis Pharma Basel, Switzerland
Hypothesis
To compare the effects of nateglinide plus metformin with gliclazide plus metformin on glycaemic control in patients with Type 2 diabetes.
Conclusion
Both nateglinide and gliclazide combined with metformin reduced HbA1c similarly, but nateglinide showed better postprandial glucose control.
Supporting Evidence
- HbA1c was significantly decreased from baseline in both treatment groups.
- The overall rate of hypoglycaemia events was similar in both groups.
- Nateglinide showed a significant reduction in maximum postprandial glucose excursion compared to gliclazide.
Takeaway
This study looked at two diabetes medications to see which one works better when added to metformin. They found both worked similarly for lowering blood sugar, but one did a better job after meals.
Methodology
Double-blind, double-dummy, parallel group, randomized, multicentre study over 24 weeks.
Potential Biases
Potential bias due to the study being sponsored by Novartis Pharma, the manufacturer of nateglinide.
Limitations
The study was limited to patients who were inadequately controlled on metformin alone and may not generalize to all Type 2 diabetes patients.
Participant Demographics
Most participants were Caucasian, with a mean age of 61.8 years and a BMI of 29.0 kg/m2.
Statistical Information
P-Value
0.099
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website